Multidisciplinary Functional MR imaging for prostate cancer

Korean Journal of Radiology

Volumn 10, Issue 6, 2009, Pages 535-551

  Kim, Jeong Kon ^a   Jang, Yun Jin ^a,b   Cho, Gyunggoo ^c  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Diffusion weighted imaging; Dynamic contrast enhanced MR; Magnetic resonance (MR); Prostate cancer; Spectroscopy

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HISTOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE CANCER; REVIEW;

CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS;

EID: 73449129316     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2009.10.6.535     Document Type: Review

References (59)

1. Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS. Functional MR imaging of prostate cancer. Radiographics 2007;27:63-75
2. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53
3. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497-505
4. Somford DM, Fütterer JJ, Hambrock T, Barentsz JO. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008;16:685-695
5. Mulkern RV, Barnes AS, Haker SJ, Hung YP, Rybicki FJ, Maier SE, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006;24:563-568
6. Moseley ME, Butts K, Yenari MA, Marks M, de Crespigny A. Clinical aspects of DWI. NMR Biomed 1995;8:387-396
7. Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28:720-726
8. Cornfeld DM, Weinreb JC. MR imaging of the prostate: 1.5T versus 3T. Magn Reson Imaging Clin N Am 2007;15:433-448
9. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology 2009;250:145-151
10. Kim JH, Kim JK, Park BW, Kim N, Cho KS. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging 2008;28:1173-1179
11. Hambrock T, Fütterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008;43:686-694
12. Coakley FV, Hricak H. Radiologic anatomy of the prostate gland: a clinical approach. Radiol Clin North Am 2000;38:15-30
13. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007;42:842-847
14. Tamada T, Sone T, Toshimitsu S, Imai S, Jo Y, Yoshida K, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 2008;27:552-556
15. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21:258-262
16. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002;16:196-200
17. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004;20:654-661
18. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 2006;41:185-188
19. Kim CK, Park BK. Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 2008;32:163-172
20. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61:297-302
21. Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008;49:602-610
22. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189:323-328
23. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152
24. Morgan VA, Kyriazi S, Ashley SE, DeSouza NM. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radiol 2007;48:695-703
25. Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology 2008;248:531-539
26. Park BK, Lee HM, Kim CK, Choi HY, Park JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008;43:789-793
27. Kim CK, Choi D, Park BK, Kwon GY, Lim HK. Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results. J Magn Reson Imaging 2008;28:963-969
28. Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001;46:1054-1058
29. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer 2007;14:163-173
30. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005;22:639-646
31. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging 2007;26:235-249
32. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-2328
33. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-458
34. Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging -- initial results. Radiology 2007;245:176-185
35. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging -- initial experience. Radiology 2004;233:709-715
36. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003;229:248-254
37. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101
38. Larsson HB, Tofts PS. Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning -- a comparison of methods. Magn Reson Med 1992;24:174-176
39. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628
40. Evelhoch J, Brown T, Chenevet T, Clarke L, Daniel B, Degani H, et al. Consensus recommendation for acquisition of dynamic contrasted-enhanced MRI data in oncology. National Cancer Institute web site. http://imaging.cancer.gov/ reportsandpublications/ReportsandPresentations/ConsensusRecommendationforA cquisitionofDynamicContrastedEnhancedMRIData. Accessed in February 5, 2009
41. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 2006;30:7-11
42. van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-287
43. Fütterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237:541-549
44. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190:1187-1192
45. Haider MA, Davidson SR, Kale AV, Weersink RA, Evans AJ, Toi A, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007;244:196-204
46. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 2009 [Epub ahead of print]
47. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109
48. Oyen RH. Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol 2003;13:921-924
49. Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 2007;189:849
50. Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, Barentsz JO, Huisman HJ. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys 2008;35:888-899
51. Fütterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680
52. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 2008;16:697-710
53. Males RG, Vigneron DB, Star-Lack J, Falbo SC, Nelson SJ, Hricak H, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22
54. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging -- clinicopathologic study. Radiology 1999;213:473-480
55. Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007;99:786-793
56. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005;236:903-910
57. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814
58. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004;183:1079-1083
59. Zakian KL, Eberhardt S, Hricak H, Shulka-Dave A, Kleinman S, Muruganandham M, et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging --initial results. Radiology 2003;229:241-247